Evidence map›Paper›PMID 28793186›Full record

ArticleACS synthetic biology2017

An Engineered Optogenetic Switch for Spatiotemporal Control of Gene Expression, Cell Differentiation, and Tissue Morphogenesis.

Lauren R Polstein, Mark Juhas, Gabi Hanna, Nenad Bursac, Charles A Gersbach

Open access · greenAbstract read
In one paragraph

Article in ACS synthetic biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
9.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Signal control during tissue regeneration in adult animals.Nature reviews. Molecular cell biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Actually Seeing What Is Going on - Intravital Microscopy in Tissue Engineering.Frontiers in bioengineering and biotechnology · 2021
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lauren R PolsteinDepartment of Biomedical Engineering, Duke University , Durham, North Carolina 27708, United States.
Mark JuhasDepartment of Biomedical Engineering, Duke University , Durham, North Carolina 27708, United States.
Gabi HannaDepartment of Radiation Oncology and Duke Cancer Institute, Duke University Medical Center , Durham, North Carolina 27710, United States.
Nenad BursacDepartment of Biomedical Engineering, Duke University , Durham, North Carolina 27708, United States.
Charles A GersbachDepartment of Biomedical Engineering, Duke University , Durham, North Carolina 27708, United States.ORCID 0000-0003-1478-4013
Duke University · USDuke Medical Center · US

Funding

University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
Engineering Targeted Epigenetic Modifiers for Precise Control of Gene RegulationR01DA036865 · NIDA · DUKE UNIVERSITY · PI CRAWFORD, GREGORY E, GERSBACH, CHARLES A. · 2013 to 2017
$2.6M
Engineering Morphogenetic Factors for Enhanced Genetic ReprogrammingDP2OD008586 · OD · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2011 to 2011
$2.4M
Muscle-macrophage constructs for skeletal muscle repairR01AR070543 · NIAMS · DUKE UNIVERSITY · PI BURSAC, NENAD · 2016 to 2020
$1.9M
Engineering a Functional Skeletal MuscleR01AR055226 · NIAMS · DUKE UNIVERSITY · PI BURSAC, NENAD · 2008 to 2012
$1.6M
Tissue Procurement and Analysis CoreP30AR066527 · NIAMS · DUKE UNIVERSITY · PI LEVINSON, HOWARD · 2014 to 2015
$1.3M
Spatially Controlled Gene Delivery of Morphogenetic Factors from Woven ScaffoldsR03AR061042 · NIAMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2011 to 2013
$224k
NIAMS NIH HHS P30 AR066527NIAMS NIH HHS R01 AR055226NIAMS NIH HHS R01 AR070543NIAMS NIH HHS R03 AR061042NIDA NIH HHS R01 DA036865NIGMS NIH HHS T32 GM008555NIH HHS DP2 OD008586
6 · The paper itself

Abstract

The precise spatial and temporal control of gene expression, cell differentiation, and tissue morphogenesis has widespread application in regenerative medicine and the study of tissue development. In this work, we applied optogenetics to control cell differentiation and new tissue formation. Specifically, we engineered an optogenetic "on" switch that provides permanent transgene expression following a transient dose of blue light illumination. To demonstrate its utility in controlling cell differentiation and reprogramming, we incorporated an engineered form of the master myogenic factor MyoD into this system in multipotent cells. Illumination of cells with blue light activated myogenic differentiation, including upregulation of myogenic markers and fusion into multinucleated myotubes. Cell differentiation was spatially patterned by illumination of cell cultures through a photomask. To demonstrate the application of the system to controlling in vivo tissue development, the light inducible switch was used to control the expression of VEGF and angiopoietin-1, which induced angiogenic sprouting in a mouse dorsal window chamber model. Live intravital microscopy showed illumination-dependent increases in blood-perfused microvasculature. This optogenetic switch is broadly useful for applications in which sustained and patterned gene expression is desired following transient induction, including tissue engineering, gene therapy, synthetic biology, and fundamental studies of morphogenesis.

Indexed as

Angiopoietin-1Cell DifferentiationGene Expression RegulationMyoD ProteinVascular Endothelial Growth Factor AAnimalsCell LineMiceOptogeneticsAngiopoietin-1Angpt1 protein, mouseMyoD1 myogenic differentiation proteinMyoD ProteinVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseangiogenesiscell transplantationlight-induciblemyogenesisoptogeneticsrecombination

Identifiers

PMID28793186
PMCPMC5767923
OpenAlexW2744706929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.